The leading CEO forum for pharmaceutical producers, distributors and retailers in Russia

24 - 25 November 2020

Corinthia Saint-Petersburg Hotel

Speaker confirmations in 2020

General Manager Sanofi Eurasia from October 1, 2018. Prior to that since January 1, 2016 worked as General Manager, Rx, Sanofi Russia & Belarus.  
Engineer by training with MBA degree from Cranfield School of Management, UK, Oxana has got more than nineteen years of in-depth knowledge and experience in pharmaceutical industry with a number of leadership roles in Marketing, Strategic Planning, and Sales in Russia and UK.  
Oxana started her career in pharmaceutical industry in 2001 with Eli Lilly UK. Over the following 13 years, she took on a number of senior management positions with increasing responsibility. In 2014, Oxana joined Sanofi as a Head of Diabetes BU in Russia.  

Since May 2017 Irina Panarina has been appointed to the position of General Manager of AstraZeneca, Russia and Eurasia. Irina is responsible for AstraZeneca business in Russia & Eurasia Area and she leads AstraZeneca Russia. Irina Panarina has worked for AstraZeneca since 2009.

In October 2015 Irina joined the Russian team as Cardiovascular and Metabolic Disease Business Unit Head. Before coming to Russia, Irina Panarina held the position of General Manager at AstraZeneca Ukraine. Prior to joining AstraZeneca Irina held regional roles at GSK Pharma headquarters in London, UK.

Irina Panarina has work experience in marketing, product portfolio management, people development. Irina Panarina has degrees from Newcastle University & South Bank University. She also holds MBA degree from INSEAD Business School. Since February 2018 Irina Panarina has been the Member of the General Council of the All Russia Public Organization “Business Russia”. In March 2018 she was elected as Business Ambassador of “Business Russia” to Sweden.

Inna Bakumenko joined Abbott as the General Manager in November 2019. The key priorities in this role are strategic portfolio development, digital transformation, and scaling up of management expertise to the country cluster. Inna has over 20 years of professional experience in the pharmaceutical industry in Russia and CIS. Prior to joining Abbott, Inna was in charge of Pfizer GEP in Russia and General Manager of Pfizer Upjoin in Russia. Early in her career, Inna worked as a medical representative of Janssen-Cilag, Johnson & Johnson’s division. Then she took various roles in sales and marketing and was in charge of business units of Servier, Allergan and Pfizer in Ukraine. From 2015 Inna was the General Manager of Pfizer in Ukraine and a regional head of GEP business in Ukraine, Caucasus and Central Asia. Inna received higher medical degree at Kharkov National Medical University and master's in marketing and management at the National Economical University by European program TACIS, and Harvard Business School.

Irina joined Eli Lilly team in 2001 as a Brand Manager, and has since advanced to General Manager of Eli Lilly Russia/CIS. For the past 20 years she had worked in key marketing and sales roles, was the head of HR function, and led the efforts to implement Six Sigma principles to refine the business processes at Lilly. Irina served as Senior Director for Ethics and Compliance, International Business Unit at the company’s headquarters in the US. Irina is currently focusing on strengthening the company’s position in oncology, diabetes and immunology in Russia and CIS as well as accelerating the path to market for Lilly’s innovative molecules. Irina obtained her MBA degree at the Weatherhead School of Management, Case Western Reserve University in Ohio, USA.

Elena is recognized expert and leader of the Russian pharmaceutical industry, has 25 years of experience in leading international pharmaceutical companies, one of 25 women CEO of Russia according to RBC. 
2019 till present – President of the company Takeda Pharmaceuticals Russia 
2014-2019 General Manager, Abbott Russia 
2011-2014 General Manager, Meda Pharmaceuticals 
1995-2011 kept different positions in sales and marketing in such pharmaceutical companies as Pliva (Croatia), Novartis Pharma (Switzerland), Sanofi (France). 
1990-1993 graduated from the Oncology Institute of Russian Academy of Sciences., PhD. 
1987 graduated from the Moscow Medical Academy n.a. Sechenov, Department of General Medicine.

Dr. Stephan Eder is Executive Vice President of STADA in the Russia and CIS region, and a member of the Global STADA Executive Committee. In this role, he oversees all operations in STADA Russia as well as in the CIS countries. Russia is with more than 3000 employees the second largest business within the global STADA Group.

He joined STADA from Sandoz, where he most recently served as CEO Hexal and Country Head Sandoz Germany from mid-2017 onwards. With a clear vision, he led the German Sandoz team and business through a strategic transformation to drive increased customer focus, resulting in strong sales and profit growth as well as an expansion of market leadership in Germany.

Having started his career at McKinsey, Austrian national Stephan Eder was co-founder and CFO of the startup medicine-discovery company 55pharma before joining Sandoz’ parent group, Novartis, in 2007. After working in corporate strategy roles at Novartis, he subsequently led Sandoz’ portfolio management, business development and licensing function in Central and Eastern Europe before he was responsible for the Russian OTC operation from mid-2010 until end 2013. During this period under his leadership, the business almost doubled in size and strongly outgrew the Russian OTC market. Subsequently until mid-2017, Stephan Eder headed Sandoz’ operations in the UK and Ireland as General Manager, successfully growing the business and driving sustainable results in a highly volatile market.

Katerina began her career with Janssen in 2001, holding a number of positions in the Sales, Marketing and Market Access teams. She has been a member of the Russian board of directors since 2010 and was appointed Country Manager Russia in 2015, and then she was promoted to the position of Managing Director Russia & CIS in 2017. In April 2019 Katerina was appointed CEO of Johnson & Johnson Russia & CIS.

Throughout her 17-year career with Janssen, Katerina has consistently demonstrated high standards of quality and strong results. She led the launch of a whole range of new products and work across a number of therapeutic areas, as well as establishing several new business units. In her role as Commercial Operations Director, Russia, Katerina successfully led commercial teams in close collaboration with other departments, which yielded great business results and drove the company’s overall success.

Katerina graduated with distinction from the International University in Moscow, where she studied law. She also completed specialist education for senior executives at the London School of Economics and Political Science and Moscow School of Management Skolkovo.

Elena owns more than15 year experience in pharma with a proven track record in driving marketing, sales, and corporate strategy development.

Elena launched her professional career in Marketing in Boehringer Ingelheim, one of the leading German pharma companies, having worked there for 10 years. Moving forward, Elena had various executive positions in Russian, American and Indian pharma companies, gaining valuable international experience and building a wide network of contacts with partners.

Elena graduated from Baikal International Business School of Irkutsk State University (Siberian-American Department of Management). Also she has a degree of Global Executive MBA of Vienna University of Economics and Business and of University of Minnesota.

Adlane graduated in Marketing and Management from Lyon Business School and holds a Master’s Degree in International Trade from Lyon University.

Adlane Soudani joined Ipsen in France in 2005. He developed a specific expertise in the export business in several regions of the globe until he was promoted to Export Director for Latin America.

Building on his success in this role, in 2013 he was appointed General Manager, Ipsen in Algeria. In this position, he has been instrumental in building a strong team and leading it to reach record market shares for both the Specialty Care and Consumer Healthcare businesses.

Demonstrating a lot of resilience in a challenging market like Russia, Adlane successfully led the creation of a Joint-Venture in the country which has paved the way for building the first oncology factory in the Algeria. 

In October 2018 Adlane was appointed a General Manager of Ipsen in Russia & CIS.

Since then the company has started its fantastic transformation journey. Within a relatively short period of time Adlane managed to develop new capabilities within the company to be more focused on innovation and breakthrough solutions in oncology and rare diseases.  Thanks to the recently launched innovative breakthrough solution for kidney cancer treatment and other product yet to come for patients` unmet needs, Ipsen is transforming into one of the key players in oncology and orphan disease markets in Russia.

Adlane`s key focus in patient centricity and development of business in a compliant manner helped to bring innovation for the development of the company which can contribute to the development of the healthcare industry in Russia.

Ivan Poljak is General Manager of Abbott’s Veropharm, one of Russia’s leading healthcare manufacturers. Before heading Abbott’s Veropharm business, Ivan held the position of Senior Director Commercial Development, Strategy and Sales in Abbott’s medicines business. 
Ivan’s experience combines international expertise with a strong understanding of country specifics, and an insight-driven approach to business. He has more than 20 years of experience leading successful teams at international healthcare companies, working in the United States, Asia and Europe. Ivan has strong experience in new product launches, life cycle management, sales force excellence and market research. 
Ivan has a Bachelor of Science degree in Business Administration from S.R. Univesity in the U.S. and an MBA from Thunderbird Graduate School of International Management in the U.S. He also completed executive education programs at INSEAD in France and Saïd Business School at the University of Oxford in Great Britain. Ivan was born in Belgrad, Serbia. He is fluent in five languages, including Russian and English.

The head of "ERKAFARM" group of companies since June 2012. Earlier, from 2009 to 2012, she has successfully performed as the deputy of General Director for Commerce. Under the leadership of Anastasia, the company has become one of the leaders in the pharmaceutical industry and from 2014 has been in the TOP-3 pharmaceutical chains in Russia. Before joining ERKAFARM, Anastasia worked for the "Protek" group of companies being the head of marketing and advertising department of the "Rigla" pharmacy chain.

The CEO of the ERKAFARM group of companies is included in the ranking of the TOP-100 economic leaders in Russia. Anastasis is among the leaders in the TOP-25 most influential female CEO ranking, which is annually published by RBC magazine, she is the manager who has never left this list since it was established. She is ranked 10th on the Kommersant newspaper's TOP-1,000 Russian Managers list in the pharmaceutical category. She was included in the TOP-1,000 most effective executives list compiled by the business publication Delovoy Peterburg.

Anastasia graduated from the State University - Higher School of Economics and also finished educational program EMBA (Executive Master of Business Admini- stration) program at Saïd Business School, University of Oxford (Oxford University Business School).

In 1988 graduated from the Chelyabinsk State Medical Institute with a specialization in «General Medicine».
In 1998 completed postgraduate studies and defended a thesis on «anesthesiology-resuscitation» and «oncology» in the P.A. Herzen Moscow Oncology Research Institute.
Worked as a practitioner in various medical institutions of the RF, held senior positions in the Ministry of Health of the RF, in the Ministry of Health of Moscow Region and in leading pharmaceutical companies: MEDSI Group of Companies, Pharmeco LLC, Biotec LLC.
Since April 2018 has taken up the position of CEO of PJSC «Pharmacy Chain 36.6»
In 2002 and 2006 the Ministry of Health of Moscow Region gave Mr. Nesterenko a commendation for his diligent work.

Graduated from the Geography Department of Kazan Federal University. Received an MBA at the Management School of Lancaster University (UK). Has over 20 years of experience in senior managerial positions in the pharmaceutical industry.

In 2011 won the “Manager of the Year” as per Platinum Ounce award, a prominent professional award in the Russian pharmaceutical field. In 2015, became the Head of the Eurasia business unit — encompassing Russia, the CIS states, Georgia and the Ukraine — in a pharmaceutical company Bosnalijek (Bosnia and Herzegovina), one of the largest pharmaceutical manufacturers in the Balkan States and Eastern Europe. Recently, the business unit led by Valentina has increased its influence by entering the markets of Kazakhstan, Belarus and Azerbaijan.

In 2017, Bosnalijek, with its production sites in Sarajevo, became one of the first companies that had its application approved by the Russian Ministry of Industry and Trade and received a GMP certificate. The Russian market is vital to Bosnalijek’s future; it is the second year in a row that Bosnalijek sales continue to grow at a double-digit rate, which is significantly faster than the market. Bosnalijek best sellers are LYSOBACT and ENTEROFURYL, ranking among Top 3 in their categories.

Graduated from the National Medical University in Odessa (Ukraine) in 2012 and completed medical residency specializing as family physician. Worked at state hospitals in psychiatry, obstetrics and gynecology, and intensive care practice. From 2013 till 2015 worked as medical representative and area manager at SB-Farma and Farmat LTD pharmaceutical companies in Ukraine. In 2015-2017 served as Head drug reimbursement and Commercial director at Olexta (Santens Group). Joined CV Protek in 2017 as Head of My Health project. In 2020 also appointed CEO of Sechenov.PRO, joint-venture by CV Protek and Sechenov Medical University.

Elena Nevolina, Ph. D. in Pharmaceutical Science, is Executive Director of the National Pharmaceutical Chamber in Russia, has an extensive experience in pharmaceutical industry since 1985

For more than 10 years, she was Head of the Control and Audit department of the Main Pharmacy Administration of Soviet Ministry of Health, later taking up executive positions in pharmaceutical associations. Now Elena Nevolina is Executive Director of association “Pharmacy Guild” (since 2006) and Executive Director of association “National Pharmaceutical Chamber” (since 2014) being an active contributor to the development of the Russian pharmaceutical industry and main self-care advocate in Russia

Elena Nevolina is an expert of the Russian Government Expert Council, a member of self-regulation Committee of the Chamber of Industry and Commerce, Executive Secretary (in pharmacy) of the Council for Professional Qualifications, an expert on regulatory impact assessment of Ministry of Health’s orders and a member of the working group of Regulatory Impact Assessment in Ministry of Economic Development

Is a member of the working group on implementation of the "regulatory guillotine" reform in the field of pharmaceuticals and medical devices of the Russian Government

Is a member of the Expert Council on Improving Medical Education and Personnel Policy in Healthcare of the State Duma of the Russian Federation.



Mariya graduated from Medical University and Clinical Residency with a specialization in Cardiology and received the education in Strategic Management at business schools in Lausanne (Switzerland) and Singapore.

Mariya began her career in the pharmaceutical business as a medical representative, then gained experience in marketing and in 2009 became the head of the Nephrology Business Unit of Amgen. Having formed a strong sales & marketing team, Maria was able to bring the company's nephrology business to a qualitatively new level, demonstrating the highest results of work in the company for two years in a row.

In 2014, Maria accepted an offer to head a completely new direction for the company, standing at the origins of the formation of the Market Access function in the Russian pharmaceutical market and the CIS markets.

In 2018, in the role of Global Value Access & policy director for Russia and CEE countries, she moved to Alexion, where, under her leadership the company's leading drugs were included in the state drug lists. In 2019, Maria joined Ipsen as Market Access and Public Affairs Director, Russia & CIS, taking a course to strengthen the company's reputation as a reliable partner of the state and society, offering innovative solutions for patients in various therapeutic areas.

Ilya received his Specialist’s degree in economics and mathematics from Financial University under the Government of the Russian Federation, and then continued his education in Diplomatic Academy of the Russian Ministry of Foreign Affairs receiving his Master’s degree in management. Ilya has more than 10 years’ extensive leadership experience at Bayer. Ilya joined the company as the Head of controlling department, then, for several years, had an international assignment in CH HQ in Switzerland. Currently he is the Head of PMO and BD&L, Cluster Russia, Ukraine and CIS. Ilya’s areas of responsibilities include business analytics and market analysis, also management of divisional strategic projects (including localization) and business development (innovations and e-commerce).

Vera graduated from The first Moscow Medical University named by I.M. Sechenov, clinical residency in the specialty "Anesthesiology and Reanimatology", and also received additional education at the Russian Medical Academy and the Institute of Additional Professional Education GASIS NRU HSE.

Vera has 5 years of experience in the healthcare as ICU Specialist, and 19 years of experience in the pharmaceutical industry in Russia and the CIS.

She began her career in the pharmaceutical business in the sales department as Medical Representative and then as District Manager for Pfizer's hospital and oncology business.

In 2006, Vera moved to the medical department and since then has been working and continuing her development in Medical Affairs, promoting from Medical Adviser to a Medical Director and gaining experience in 4 major international pharmaceutical companies in various therapeutic areas: oncology, onco-hematology, orphan diseases, ophthalmology, ICU, neurology, aesthetics, as well as in the vast field of infectious diseases.

In 2015 Vera was appointed Medical Director of Alexion Pharma, where she was responsible for Russia and the CIS. In this role, Vera managed to form a professional team of the medical department, with which she launched patient support and education programs, educational programs for doctors, increased the compliance of the company's medical processes, which was recognized by the global leadership as the best practice.

In 2019, she joined Ipsen as Medical Director for Russia and the CIS. Under Vera's leadership, Ipsen's medical function underwent a significant transformation, becoming one of the key drivers of the company's development.

+ 10 years of working experience in public

administration in customer Service, and

at Merck in the supply chain management

of medicinal products


Current Position

Since February 2018: Supply Chain Head, Merck Biopharma Russia & CIS


Professional background

2015 ~ 18  Demand Planning Manager; Merck Spain

2012 ~ 15  Customer Service Technician, Customer Service Manager; Open    Administration Consortium

2006 ~ 12  Product Manager, Project Manager; Catalan Certification Agency

Tatarnikova Anastasia Aleksandrovna, journalist and manager economist by education, has been involved in public activities in the field of Rare Diseases since 2011.

She is the head of the organization for patient care - ICO "Another Life" and the Chairman of the "Center for expert assistance on issues related to Rare Diseases “Home for Rares”. In addition to providing organizational, legal, informational and other kind of assistance to the patients in the exact nosological areas, ANO “Home for Rares” and its experts are active participants of regional and federal socio-political events aimed at improving the quality and availability of medical care and drug provision for "rare" patients.

Vilena Galkina

Head of Government Relations Department, GEROPHARM

Vilena graduated from the State University of Management with a degree in Public Relations in 2008. In 2018, she completed additional education at the St. Petersburg State Chemical and Pharmaceutical University, Department for Regulation of Circulation of Medicines in Pharmaceutical Market.

 Her professional experience in pharmaceutical business goes back to 2008. She worked in consulting companies cooperating with major international and Russian companies.

 In 2012, she joined GEROPHARM. Vilena is an expert and a regular participant in discussions on topical issues related to industry regulation.

Rustam Iksanov, Vice President, R&D, co-developer of more than 10 inventions in the field of pharmacy, which are protected by patents of the Russian Federation.

 Rustam Iksanov has been working in the Russian pharmaceutical market for more than 20 years. Before joining NovaMedica he took the position of M&A Director in Valenta Pharm where he managed the business development of Gastroenterology division. He developed strategic scenarios of product portfolio development, managed pipeline projects and was responsible for search of potential targets for acquisition (products, developments and companies), preparation and implementation of deals.

Earlier Rustam was Vice President for Strategic Development in Akrikhin (Polpharma), he also hold managerial positions in the field of development products and product portfolio in Izvariono Pharma (Ferring Pharmaceuticals) and Nizhpharm (Stada). Before that, he held classes at the Nizhny Novgorod State Medical Academy and worked as a physician.

Rustam graduated with honors from the Nizhny Novgorod State Medical Academy. In addition, he undertook special programs devoted to commercialization of technologies in the Russian Presidential Academy of National Economy and to pharmaceutical management and economics in the Peoples’ Friendship University of Russia.

Director of the Federal State Unitary Enterprise “The Saint Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial Preparations” of the Federal Medical and Biologic Agency.

Since January 2019, Irina Romanova has headed Sanofi's Consumer Healthcare business in the Eurasia zone. Prior to that, since 2016, Irina was leading CHC business in Russia and Belarus in the role of General Manager. Irina started her career in the pharmaceutical industry over 20 years ago as a medical representative. Through this journey, she held various positions to drive profitable growth and market share gains within International pharma companies, such as Nycomed and Novartis.

Anastasia Altaychinova joined Sanofi's Consumer Healthcare sales team in April 2017, as Head of Excellence. In December 2018, Anastasia was appointed as Customer Development Head to lead a newly created department, and later in July 2019, she was promoted to the position of National Sales Manager. Anastasia received her medical degree at the I.M. Sechenov First Moscow State Medical University, with major in obstetrician-gynecologist. After graduation she worked in sales departments at various leading pharmaceutical companies such as Bayer and MSD, where she was responsible for prescription and OTC drug portfolios.

Kirill has over 10 years of experience in leadership positions at top international pharmaceutical companies such as Abbott, Novartis and Takeda.
In 1998 Kirill graduated from the Faculty for Training of Scientific and Pedagogical Personnel at Sechenov Moscow Medical Academy, and in 1999 degree International Master of Public Health at Hebrew University-Hadassah Braun School of Public Health and Community Medicine (Jerusalem, Israel). In 2003, Kirill defended PhD thesis from the Faculty of Healthcare Management of the Sechenov Moscow Medical Academy. In 2006 he received Doctor of Philosophy degree from the London School of Hygiene and Tropical Medicine, and in 2011 received Doctor of Medical Sciences degree from the Sechenov Moscow Medical Academy
Kirill is a professor of Health Care Administration and Economy program at Higher School of Economics. He has more than 50 scientific publications.

As Director General, Ms Svarcaite is responsible for providing strategic direction and leadership while managing the day to day operations of Association of the European Self-Care Industry (AESGP) and its ongoing relationships with its member associations, companies and other stakeholders, as well as representing the self-care industry in various International, European and national forums. The Association of the European Self-care Industry (AESGP) represents the manufacturers of non-prescription medicines, food supplements and self-care medical devices in Europe, an area also referred to as consumer healthcare products. Her previous work experience includes the Secretary General position at the Pharmaceutical Group of the EU (PGEU), an umbrella organization representing community pharmacy in Europe, the head of Pharmaceutical Care Department in a major pharmacy chain in Lithuania. Ms. Svarcaite received her Master in Pharmacy degree from Kaunas University of Medicine, Kaunas, Lithuania. She went on to earn her Master of Science degree in Pharmacy Practice from The School of Pharmacy, University of London.